医药生物/中药Ⅱ 余汝意（分析师） 巢舒然（联系人） yuruyi@kysec.cn 证书编号：S0790523070002 chaoshuran@kysec.cn 证书编号：S0790123110015 东阿阿胶（000423.SZ） 一季度业绩稳增，现金流短期承压不改长期向好信心 2025 年 04 月 30 日 投资评级：买入（维持） | 日期 | 2025/4/29 | | --- | --- | | 当前股价(元) | 54.00 | | 一年最高最低(元) | 72.91/44.62 | | 总市值(亿元) | 347.75 | | 流通市值(亿元) | 347.75 | | 总股本(亿股) | 6.44 | | 流通股本(亿股) | 6.44 | | 近 3 个月换手率(%) | 60.45 | 股价走势图 -40% -20% 0% 20% 40% 2024-04 2024-08 2024-12 东阿阿胶 沪深300 数据来源：聚源 相关研究报告 《经营业绩增速亮眼，2025 年深化产 业布局突破发展—公司信息更新报 告》-2025.3.19 《"药品+健康消费品"双轮驱动，滋 补品牌焕新生—公 ...

证券研究报告 | 公司点评 | 中药Ⅱ 云南白药(000538) 报告日期：2025 年 04 月 29 日 业绩略超预期，持续挖潜增效 ——云南白药 2025 年一季报点评 投资要点 ❑ 风险提示：政策调整风险、成本波动风险、市场竞争加剧 | | | | [Table_Forcast] (百万元) | 2024 | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业收入 | 40033 | 40691 | 42276 | 43753 | | (+/-) (%) | 2.36% | 1.64% | 3.90% | 3.49% | | 归母净利润 | 4749 | 5327 | 5945 | 6554 | | (+/-) (%) | 16.02% | 12.16% | 11.60% | 10.26% | | 每股收益(元) | 2.66 | 2.99 | 3.33 | 3.67 | | P/E | 21.76 | 19.40 | 17.38 | 15.76 | 资料来源：公司年报，浙商证券研究所 -17% -10% -3% 4% 12% 19 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][3] Core Views - The company has shown impressive growth in operating performance, with a revenue of 1.777 billion yuan in 2024, representing a year-on-year increase of 9.15%. The net profit attributable to the parent company reached 255 million yuan, up 36.61% year-on-year [3][4] - The company is focusing on innovative traditional Chinese medicine, which is expected to enhance long-term competitiveness and growth potential [3][5] - The company has increased its profit forecasts for 2025-2027, expecting net profits of 308 million yuan, 378 million yuan, and 457 million yuan respectively [3][6] Financial Performance - In 2024, the company achieved a gross margin of 71.85%, an increase of 3.75 percentage points, and a net margin of 14.06%, up 3.03 percentage points [3][6] - The revenue from cardiovascular drugs was 530 million yuan, a growth of 37.95%, while revenue from respiratory drugs was 213 million yuan, up 18.87% [4][6] - R&D expenses increased by nearly 30% in 2024, totaling 139 million yuan, indicating a strong commitment to innovation [5][6] Earnings Forecast - The earnings per share (EPS) for 2025, 2026, and 2027 are projected to be 0.70 yuan, 0.86 yuan, and 1.04 yuan respectively, with corresponding price-to-earnings (P/E) ratios of 14.1, 11.5, and 9.5 [3][6] - The company expects a revenue growth of 14.3% in 2025, followed by 13.1% in 2026 and 13.9% in 2027 [6][8] R&D and Innovation - The company has established a comprehensive scientific management system for new drug development, integrating five major R&D platforms [5][6] - As of the end of 2024, one innovative traditional Chinese medicine product has been submitted for production approval, with five others in various clinical research stages [5][6]

证券研究报告·公司点评报告·中药Ⅱ 东阿阿胶（000423） 2025 年一季报点评：业绩符合预期，高分红， 稳增长 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 4,715 | 5,921 | 6,878 | 7,859 | 8,918 | | 同比（%） | 16.66 | 25.57 | 16.16 | 14.26 | 13.47 | | 归母净利润（百万元） | 1,151 | 1,557 | 1,864 | 2,215 | 2,565 | | 同比（%） | 47.55 | 35.29 | 19.73 | 18.80 | 15.83 | | EPS-最新摊薄（元/股） | 1.79 | 2.42 | 2.89 | 3.44 | 3.98 | | P/E（现价&最新摊薄） | 30.84 | 22.79 | 19.04 | 16.02 | 13.83 | [Table_Tag] [Table_Summa ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][6][8] Core Views - The company achieved a revenue of 35.01 billion yuan in 2024, representing a year-on-year growth of 5.72%, and a net profit attributable to shareholders of 7.23 billion yuan, up 27.19% year-on-year [6][7] - The company is focusing on its pharmaceutical core business, demonstrating strong operational resilience, with significant growth in prescription drug sales due to the expansion into nearly 5,000 hospitals and primary healthcare institutions [6][7] - The company completed the acquisition of Yingu Pharmaceutical, enhancing its product portfolio with high-tech formulations, while maintaining a high dividend payout ratio of 70.64% [6][7] Financial Summary - Revenue projections for 2024 to 2027 are as follows: 35.01 billion yuan (2024), 41.80 billion yuan (2025E), 47.44 billion yuan (2026E), and 52.91 billion yuan (2027E), with respective growth rates of 5.72%, 19.41%, 13.49%, and 11.53% [2][6] - Net profit attributable to shareholders is projected to grow from 7.23 billion yuan in 2024 to 11.22 billion yuan in 2027, with growth rates of 27.19%, 17.18%, 15.17%, and 15.03% respectively [2][6] - The company’s earnings per share (EPS) is expected to increase from 1.27 yuan in 2024 to 1.98 yuan in 2027, with corresponding P/E ratios decreasing from 17.20 to 11.08 [2][6] Profitability and Growth - The company’s net profit margin and return on equity (ROE) are projected to improve, with net profit margins of 20.64% in 2024 and 21.20% in 2027, and ROE increasing from 24.58% to 29.53% over the same period [7] - The gross margin for the manufacturing sector is expected to be 77.05% in 2024, reflecting a year-on-year increase of 3.59 percentage points [6][7] Strategic Outlook - The company is expected to maintain double-digit growth in its core business, driven by the strengthening of its "evidence-based traditional Chinese medicine" label and the expansion of its hospital network [6][7] - The OTC business is anticipated to recover due to improved online and offline marketing strategies [6][7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's profitability is steadily improving, with revenue and profit reaching a new quarterly high [1] - The core products are showing robust growth, and the company's profit margins are being maintained despite price pressures from collective procurement [8] - The company is expected to continue its growth trajectory, particularly in the OTC market, while maintaining a high dividend payout ratio [8] Financial Performance Summary - Total revenue for 2024 is projected at 25.78 billion yuan, a year-on-year increase of 32.71% [8] - Net profit attributable to shareholders for 2024 is expected to be 5.08 billion yuan, also reflecting a 32.60% increase [8] - The earnings per share (EPS) for 2024 is forecasted to be 0.72 yuan, with a price-to-earnings (P/E) ratio of 21.99 [1][9] Product Performance Summary - The revenue from the Wuling series is expected to reach 14.38 billion yuan in 2024, with a year-on-year growth of 17.14% [8] - The Chinese herbal medicine series is projected to generate 6.73 billion yuan in revenue, marking a significant increase of 46.02% [8] - The revenue from Chinese herbal formula granules is anticipated to grow by 143.19%, reaching 1.02 billion yuan [8] Future Projections - The company’s net profit is projected to reach 6.55 billion yuan in 2025 and 8.41 billion yuan in 2026, with corresponding P/E ratios of 17 and 13 [8] - By 2027, the net profit is expected to reach 10.41 billion yuan, with a P/E ratio of 11 [1][9]

2025 年 04 月 22 日 投资评级：买入（维持） | 日期 | 2025/4/21 | | --- | --- | | 当前股价(元) | 19.42 | | 一年最高最低(元) | 29.20/18.22 | | 总市值(亿元) | 38.50 | | 流通市值(亿元) | 38.50 | | 总股本(亿股) | 1.98 | | 流通股本(亿股) | 1.98 | | 近 3 个月换手率(%) | 71.64 | 医药生物/中药Ⅱ 寿仙谷（603896.SH） 股价走势图 -32% -16% 0% 16% 32% 2024-04 2024-08 2024-12 寿仙谷 沪深300 数据来源：聚源 相关研究报告 《2024H1 营收小幅下滑，市场渠道稳 步拓展 — 公 司 信 息 更 新 报 告 》 -2024.8.29 《营收利润小幅承压，营销改革赋能 品 牌 发 展 — 公 司 信 息 更 新 报 告 》 -2024.4.27 经营业绩相对承压，省外营销改革有望带来成长动力 ——公司信息更新报告 | 余汝意（分析师） | 巢舒然（联系人） | | --- | --- | | yuruyi@kys ...